# What did the Semax studies in people test?

Published November 19, 2026 · Updated November 19, 2026 · Data as of November 15, 2026

Studies in people tested [Semax](https://pepbank.io/p/semax) after ischemic stroke, on blood lipids in psoriasis, and on brain scans in healthy volunteers. [1, 2, 3, 4] As of November 15, 2026, PepBank holds 12 publications with findings in people and 99 with findings in animals. [5] Its records list 0 registered trials that test Semax. [5] PepBank's regulatory record shows Semax approved in Russia only, registered as Семакс. [6]

## Key points

- In a trial in adults after ischemic stroke, Semax raised plasma brain-derived neurotrophic factor (BDNF) levels. The levels stayed high for the whole study. [2]
- In a trial in patients with acute ischemic stroke, doctors added Semax to intensive therapy. This increased the regress of general cerebral disorders compared with conventional therapy. [1]
- In patients with psoriasis and metabolic syndrome, adding intranasal Semax lowered initially elevated total cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol. [3]
- In healthy volunteers, intranasal Semax was linked to a greater volume of part of the default mode network on resting state scans, compared with placebo. [4]
- PepBank's records list 0 registered trials that test Semax, as of November 15, 2026. [5]

## Where is Semax registered as a medicine?

PepBank's regulatory record shows Semax approved in Russia only, registered as Семакс. [6] In Russia, Семакс is a prescription-only medicine in nasal drops from the holder Peptogen. [6] One listed indication is the acute period of moderate to severe ischemic stroke, as part of combined therapy. [6]

As of November 15, 2026, PepBank holds 12 publications with findings in people and 99 with findings in animals. [5] It also holds 24 publications with laboratory findings in cells or tissue. [5] Its records list 0 registered trials that test Semax. [5]

Semax is one of the [peptides in PepBank](https://pepbank.io/peptides), with 130 studies that report results. [5] The [Semax studies](https://pepbank.io/p/semax/studies) hold 36 findings in people, against 331 findings in animals. [5]

Curo, a peptide shop with the same owner as PepBank, has a related article. [Semax vs Selank: Two Russian Peptides, Two Different Research Paths](https://curo.you/insights/semax-vs-selank-differences)

## What did the stroke studies in people measure?

In a trial in patients with acute hemispheric ischemic stroke, doctors added Semax to combined intensive therapy. It increased the regress of general cerebral disorders compared with conventional therapy. [1] The same trial in patients found more regress of focal, especially motor, disorders. [1]

In another trial in adults after ischemic stroke, Semax raised plasma brain-derived neurotrophic factor (BDNF) levels. The levels stayed high for the whole study, regardless of when rehabilitation started. [2] In that trial in people, Semax and high BDNF levels made recovery faster and better on the Barthel index. [2]

## What did the lipid study in psoriasis find?

In a trial in patients with psoriasis and metabolic syndrome, doctors added intranasal Semax to conventional therapy. It lowered initially elevated total cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol. [3] In the same patients, it raised initially reduced high-density lipoprotein (HDL) cholesterol, while standard treatment had no significant effect. [3]

## What did brain scans in healthy volunteers show?

In a study in healthy people, intranasal Semax was linked to a greater volume of the rostral part of the default mode network. This showed on resting state functional MRI (fMRI), compared with placebo. [4] In another study in healthy people, Semax injection changed resting-state connectivity between the right amygdala and the right temporal cortex. [7]

## How strong is this evidence in people?

The listed findings in people come from non-randomized trials, observational studies and one study of another design. None of them is a randomized controlled trial. [1, 2, 3, 4, 7, 8] PepBank's records list 0 registered trials that test Semax. [5]

In the acute stroke trial in patients, the researchers compared Semax with conventional therapy, without random assignment. [1] So the results in patients describe the people in these studies. They do not show how far the effects reach. [1, 2, 3] PepBank lists the stroke, lipid and brain scan findings under the [evidence class](https://pepbank.io/methods) for people. [1, 2, 3, 4]

## FAQ

### Did researchers study Semax for eye disease in people?

In a trial in patients with optic nerve disease, adding Semax to the therapeutic complex improved visual functions. [9] In those patients, visual acuity and color vision also improved. [9] In a trial in patients with non-proliferative diabetic retinopathy, both Semax groups showed positive changes in visual characteristics. [10] In those patients, the most pronounced and long-standing effect came with endonasal Semax electrophoresis. [10]

### What else did researchers test Semax for in people?

In a trial in patients with refractory peptic ulcers, the patients received intranasal Semax with traditional drugs. [11] Ulcers healed in 89.5% of these patients, versus 30.8% in the control group. [11] In patients with motor neuron disease, Semax did not change the course of chronic partial denervation, though quality of life improved. [12]

### What side effects did Semax show in people?

In an observational study in patients with cerebrovascular insufficiency, Semax had a minor percent of side effects. [8] The same study in patients found Semax well tolerated, including by older age groups. [8] In a study in patients with posthypoxic encephalopathy, an electroencephalogram (EEG) showed episodes of paroxysmal activity after Semax injection in some cases. [13]

### How much Semax research did researchers do in animals?

As of November 15, 2026, PepBank holds 99 publications with findings in animals for Semax, with 331 findings. [5] It holds 12 publications with findings in people. [5] In rats after cerebral ischemia, Semax enhanced transcription of the Bdnf gene in the cortex. [14] In rats, Semax also enhanced transcription of TrkA and TrkC in the cortex. [14]

## Sources

1. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997-01-01. https://pubmed.ncbi.nlm.nih.gov/11517472/ PMID 11517472. Evidence class: human.
2. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018-01-01. https://pubmed.ncbi.nlm.nih.gov/29798983/ PMID 29798983. Evidence class: human.
3. [POSSIBLE DRUG CORRECTION OF LIPID METABOLISM DISTURBANCES ASSOCIATED WITH METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS]. Eksperimental'naia i klinicheskaia farmakologiia, 2015-01-01. https://pubmed.ncbi.nlm.nih.gov/27051926/ PMID 27051926. Evidence class: human.
4. Effects of Semax on the Default Mode Network of the Brain. Bulletin of experimental biology and medicine, 2018-09-17. https://pubmed.ncbi.nlm.nih.gov/30225715/ PMID 30225715. Evidence class: human.
5. Semax in PepBank. PepBank, 2026-11-15. https://pepbank.io/p/semax
6. Semax: regulatory status in PepBank. PepBank, 2026-10-30. https://pepbank.io/p/semax
7. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020-01-01. https://pubmed.ncbi.nlm.nih.gov/32342318/ PMID 32342318. Evidence class: human.
8. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2005-01-01. https://pubmed.ncbi.nlm.nih.gov/15792140/ PMID 15792140. Evidence class: human.
9. [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]. Vestnik oftalmologii, 2000-01-01. https://pubmed.ncbi.nlm.nih.gov/10741256/ PMID 10741256. Evidence class: human.
10. [The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy]. Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury, 2013-09-01. https://pubmed.ncbi.nlm.nih.gov/24437205/ PMID 24437205. Evidence class: human.
11. Therapy of peptic ulcer with semax peptide. Bulletin of experimental biology and medicine, 2002-07-01. https://pubmed.ncbi.nlm.nih.gov/12459874/ PMID 12459874. Evidence class: human.
12. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2007-01-01. https://pubmed.ncbi.nlm.nih.gov/18379501/ PMID 18379501. Evidence class: human.
13. [Use of semax at a follow-up of patients with posthypoxic encephalopathy]. Anesteziologiia i reanimatologiia, 1999-01-01. https://pubmed.ncbi.nlm.nih.gov/10199046/ PMID 10199046. Evidence class: human.
14. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and molecular neurobiology, 2009-07-25. https://pubmed.ncbi.nlm.nih.gov/19633950/ PMID 19633950. Evidence class: animal.

How this article is made: PepBank writes its articles from the studies and records in its database. Each claim links to its source. [Read how PepBank collects and classes evidence.](https://pepbank.io/methods)

Canonical: https://pepbank.io/blog/what-did-the-semax-studies-in-people-test

This is not medical advice.
